標(biāo)題: Titlebook: Anticancer Drug Development Guide; Preclinical Screenin Beverly A. Teicher (Vice President and Director of Book 2004 Springer Science+Busin [打印本頁] 作者: Coenzyme 時間: 2025-3-21 19:27
書目名稱Anticancer Drug Development Guide影響因子(影響力)
書目名稱Anticancer Drug Development Guide影響因子(影響力)學(xué)科排名
書目名稱Anticancer Drug Development Guide網(wǎng)絡(luò)公開度
書目名稱Anticancer Drug Development Guide網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Anticancer Drug Development Guide被引頻次
書目名稱Anticancer Drug Development Guide被引頻次學(xué)科排名
書目名稱Anticancer Drug Development Guide年度引用
書目名稱Anticancer Drug Development Guide年度引用學(xué)科排名
書目名稱Anticancer Drug Development Guide讀者反饋
書目名稱Anticancer Drug Development Guide讀者反饋學(xué)科排名
作者: Pericarditis 時間: 2025-3-21 23:48 作者: bronchiole 時間: 2025-3-22 03:56 作者: 煩憂 時間: 2025-3-22 08:10 作者: 考博 時間: 2025-3-22 12:23 作者: Detonate 時間: 2025-3-22 15:22 作者: PLE 時間: 2025-3-22 19:17
Spontaneously Occurring Tumors in Companion Animals as Models for Drug Development (i.e., dog and cat pet population). Companion animals with naturally occurring tumors, although presently underutilized, have and should continue to provide an excellent opportunity to investigate many aspects of malignancy from etiology to treatment.作者: Kidney-Failure 時間: 2025-3-22 23:49
https://doi.org/10.1007/978-3-540-34049-2 brief history of the in vivo screens used by the NCI, (2) a description of the human tumor xenograft systems that are employed in preclinical drug development, and (3) a discussion of how these xenograft models are employed for both initial efficacy testing as well as detailed drug evaluations.作者: 戲法 時間: 2025-3-23 01:26
Human Tumor Xenograft Models in NCI Drug Development brief history of the in vivo screens used by the NCI, (2) a description of the human tumor xenograft systems that are employed in preclinical drug development, and (3) a discussion of how these xenograft models are employed for both initial efficacy testing as well as detailed drug evaluations.作者: seduce 時間: 2025-3-23 08:52 作者: Exonerate 時間: 2025-3-23 13:00
Hardware eingebetteter Systeme,reduced level. This chapter reviews their past and present role in the evaluation of anticancer drugs. Data on the sensitivity to clinically useful drugs of these two leukemias and the drug-resistant P388 sublines are reported.作者: Cursory 時間: 2025-3-23 15:50 作者: certitude 時間: 2025-3-23 22:06
Karsten Berns,Schürmann Bernd,Mario Trapp (DTP) at its internet website (.). What follows here is intended as an historical and personal perspective on how the 60-cell screen came to be and the value and legitimacy of the screen as a research tool. I attempt to convey a sense of the breadth and depth of the diverse participants and their c作者: 擺動 時間: 2025-3-23 22:38 作者: Osteoporosis 時間: 2025-3-24 02:35
https://doi.org/10.1007/978-3-540-34049-2pt foreign tissues for human tumor transplantation. The modern era is characterized by new orthotopic transplant methodologies that allow human tumors to express their metastatic potential, especially the models developed in our laboratory that are constructed by surgical orthotopic implantation wit作者: antipsychotic 時間: 2025-3-24 09:11
Hardware eingebetteter Systeme,hypothesis that a few viable malignant cells with proliferative capacity remain after therapy and eventually repopulate the primary tumor and/or grow into metastatic lesions. These minimal residual tumor cells exist at levels below detectability by standard techniques. Dendritic cell (DC)-based canc作者: 值得尊敬 時間: 2025-3-24 11:23 作者: PATHY 時間: 2025-3-24 18:21 作者: BORE 時間: 2025-3-24 19:20 作者: entail 時間: 2025-3-24 23:26 作者: chlorosis 時間: 2025-3-25 05:54 作者: orient 時間: 2025-3-25 09:33 作者: 閃光你我 時間: 2025-3-25 15:06
Patient-Like Orthotopic Metastatic Models of Human Cancerpt foreign tissues for human tumor transplantation. The modern era is characterized by new orthotopic transplant methodologies that allow human tumors to express their metastatic potential, especially the models developed in our laboratory that are constructed by surgical orthotopic implantation wit作者: 儀式 時間: 2025-3-25 17:15
Models for Biomarkers and Minimal Residual Tumorhypothesis that a few viable malignant cells with proliferative capacity remain after therapy and eventually repopulate the primary tumor and/or grow into metastatic lesions. These minimal residual tumor cells exist at levels below detectability by standard techniques. Dendritic cell (DC)-based canc作者: Foreknowledge 時間: 2025-3-25 20:19
Nonclinical Testingts outweigh the potential risks to the patient. From a business perspective, with efficiency being the key to survival, success is most often measured by the company’s ability to reach its destination in the most expeditious manner while using the fewest resources and without compromising the qualit作者: Ventricle 時間: 2025-3-26 02:34
Nonclinical Testing for Oncology Drug ProductsELs) do not have to be defined, and only minimal nonclinical proof-of-concept studies need to be provided. Nonetheless, the difficulty and importance of providing a relevant nonclinical safety assessment program is greatly increased because the first patients treated with a new oncology drug are mos作者: CURB 時間: 2025-3-26 05:56 作者: jocular 時間: 2025-3-26 08:58
Book 2004ty against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earlies作者: 說不出 時間: 2025-3-26 13:19 作者: 駭人 時間: 2025-3-26 18:32
Lino Schmid,Thomas Holleczek,Gerhard Tr?ster important role in drug evaluation, but with the development of a large number of cytotoxic drugs, animal models are too costly and the delay is too long for these models to be used for large-scale screening.作者: CHURL 時間: 2025-3-26 21:56
Lino Schmid,Thomas Holleczek,Gerhard Tr?ster important role in drug evaluation, but with the development of a large number of cytotoxic drugs, animal models are too costly and the delay is too long for these models to be used for large-scale screening.作者: 痛得哭了 時間: 2025-3-27 03:18 作者: syncope 時間: 2025-3-27 08:37 作者: Vasodilation 時間: 2025-3-27 09:48 作者: apropos 時間: 2025-3-27 15:45 作者: Between 時間: 2025-3-27 18:54
https://doi.org/10.1007/978-3-540-34049-2, experimental agents have limited antiproliferative data against a broad spectrum of human cancers, and these agents usually are then tested in the NCI’ s in vitro anticancer drug screen. Data from the screen permits the identification of agents that exhibit differential activity among multiple tum作者: CANT 時間: 2025-3-27 22:50 作者: 依法逮捕 時間: 2025-3-28 03:41 作者: 眼界 時間: 2025-3-28 08:51 作者: Gorilla 時間: 2025-3-28 10:26
https://doi.org/10.1007/978-3-540-34049-2novative therapies. Most of this work has been performed on inbred rodent models and laboratory-derived canine populations. Working with inbred populations in controlled, artificial laboratory environments raises some degree of concern over the applicability of information as it relates to naturally作者: 鋼筆尖 時間: 2025-3-28 15:03 作者: 不真 時間: 2025-3-28 22:25 作者: 情感脆弱 時間: 2025-3-28 23:46 作者: OVER 時間: 2025-3-29 04:45
Beverly A. Teicher (Vice President and Director ofIncludes supplementary material: 作者: Harridan 時間: 2025-3-29 09:13 作者: GRAVE 時間: 2025-3-29 14:41 作者: semiskilled 時間: 2025-3-29 18:21
https://doi.org/10.1007/978-1-59259-739-0cancer; cell; clinical trial; drug; drug development; drug discovery; leukemia; research; screening; tumor作者: Detain 時間: 2025-3-29 22:44 作者: 一起平行 時間: 2025-3-30 00:16
https://doi.org/10.1007/978-3-540-34049-2The classic question in the field of drug discovery is: Which tumor model is a satisfactory predictor for cancer in humans? The classic answer is: None of them!作者: pineal-gland 時間: 2025-3-30 04:02
In Vivo Methods for Screening and Preclinical TestingThe classic question in the field of drug discovery is: Which tumor model is a satisfactory predictor for cancer in humans? The classic answer is: None of them!作者: occult 時間: 2025-3-30 10:47 作者: 祖?zhèn)?nbsp; 時間: 2025-3-30 15:33 作者: tangle 時間: 2025-3-30 20:24 作者: 保全 時間: 2025-3-31 00:26 作者: glucagon 時間: 2025-3-31 01:48
Human Tumor Xenograft Models in NCI Drug Developmentedition of this book .. In addition, a series of review articles have charted the evolution of the overall NCI drug discovery process, which began in 1955 .. Although the methodologies associated with xenograft model testing have remained fundamentally the same, during the past 10 yr a series of imp作者: 可互換 時間: 2025-3-31 05:44
NCI Specialized Procedures in Preclinical Drug Evaluations, experimental agents have limited antiproliferative data against a broad spectrum of human cancers, and these agents usually are then tested in the NCI’ s in vitro anticancer drug screen. Data from the screen permits the identification of agents that exhibit differential activity among multiple tum作者: 捏造 時間: 2025-3-31 12:02
Patient-Like Orthotopic Metastatic Models of Human Cancercancer to test and investigate the hypothesis of Paget as well as for treatment and drug discovery. Thus, there has been a critical need in cancer treatment and research for rodent models that are clinically relevant. Ideal models would allow the transplantation of the majority of human tumors such 作者: angiography 時間: 2025-3-31 14:17
